Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Study of Crizotinib for ROS1 and MET Activated Lung Cancer (CROME)

NCT04084717 is registered in ClinicalTrials.gov with University Health Network, Toronto as lead sponsor.

NCT NCT04084717
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04084717 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Study of Crizotinib for ROS1 and MET Activated Lung Cancer (CROME)
Lead sponsor
University Health Network, Toronto
Phase
Phase 2
Overall status
Completed
Start date
December 3, 2019
Completion date
December 30, 2024
Enrollment
33 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

met activating mutation, met amplification, non-squamous non-small-cell lung cancer, ros1 gene rearrangement, stage iv non-small cell lung cancer